PMID- 35195549
OWN - NLM
STAT- MEDLINE
DCOM- 20220412
LR  - 20220412
IS  - 1537-162X (Electronic)
IS  - 0362-5664 (Linking)
VI  - 45
IP  - 2
DP  - 2022 Mar-Apr 01
TI  - Effectiveness of Atomoxetine (Strattera) for the Treatment of Poststroke Aphasia 
      Combined With Cognitive Impairment.
PG  - 17-20
LID - 10.1097/WNF.0000000000000495 [doi]
AB  - OBJECTIVE: In this study, we aimed for the first time to evaluate the 
      effectiveness of atomoxetine (Strattera) in the treatment of cognitive impairment 
      and aphasia after stroke in a large sample. METHODS: We reviewed the data of 106 
      patients with poststroke aphasia and cognitive impairment (atomoxetine treatment 
      group = 55 patients vs control group = 51 patients), including scores of the 
      Korean version of the Mini-Mental State Examination (K-MMSE) and the Korean 
      version of the Western Aphasia Battery. Wilcoxon signed-rank tests were used to 
      compare the initial and follow-up K-MMSE and Korean version of the Western 
      Aphasia Battery scores. Mann-Whitney U tests were used to compare the degree of 
      improvement in K-MMSE and Aphasia Quotient (AQ) scores between the atomoxetine 
      and control groups. RESULTS: Baseline characteristics including age, years of 
      education, and scores of the initial Functional Independence Measure, Korean 
      version of the Modified Barthel Index, Hamilton Depression Rating Scale, K-MMSE, 
      and AQ did not differ significantly between the 2 groups. Follow-up K-MMSE and AQ 
      scores were significantly better than the initial scores in both the treatment 
      and control groups. However, improvements in K-MMSE scores were significantly 
      greater in the treatment group than in the control group. In addition, the 
      atomoxetine group had significantly higher AQ scores than the control group, 
      especially for auditory verbal comprehension and naming. CONCLUSIONS: Atomoxetine 
      has been shown to significantly improve cognitive function and language in 
      patients with poststroke aphasia. It is also the first study to report 
      improvement in auditory comprehension and naming by administration of 
      atomoxetine.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Park, Jong Mi
AU  - Park JM
AD  - Department and Research Institute of Rehabilitation Medicine, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Choi, Soojin
AU  - Choi S
FAU - Kim, Yong Wook
AU  - Kim YW
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Neuropharmacol
JT  - Clinical neuropharmacology
JID - 7607910
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
SB  - IM
MH  - *Aphasia/drug therapy/etiology/rehabilitation
MH  - Atomoxetine Hydrochloride/therapeutic use
MH  - *Cognitive Dysfunction/drug therapy/etiology
MH  - Humans
MH  - Mental Status and Dementia Tests
MH  - *Stroke/complications
COIS- Conflicts of Interest and Source of Funding: The authors have no conflicts of 
      interest to declare.
EDAT- 2022/02/24 06:00
MHDA- 2022/04/13 06:00
CRDT- 2022/02/23 12:26
PHST- 2022/02/24 06:00 [pubmed]
PHST- 2022/04/13 06:00 [medline]
PHST- 2022/02/23 12:26 [entrez]
AID - 00002826-900000000-99431 [pii]
AID - 10.1097/WNF.0000000000000495 [doi]
PST - ppublish
SO  - Clin Neuropharmacol. 2022 Mar-Apr 01;45(2):17-20. doi: 
      10.1097/WNF.0000000000000495.